{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:08:09Z","timestamp":1792609689797,"version":"4.5.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Recombinant factor VIII (<jats:styled-content style=\"fixed-case\">rFVIII<\/jats:styled-content>) products provide a safe and efficacious replacement therapy for prevention and treatment of bleeding episodes in patients with haemophilia A. The present investigations from the multinational, open\u2010label guardian<jats:sup>\u2122<\/jats:sup> clinical trials assessed the haemostatic response of turoctocog alfa (NovoEight<jats:sup>\u00ae<\/jats:sup>), a <jats:styled-content style=\"fixed-case\">rFVIII<\/jats:styled-content> product, in patients with severe haemophilia A (FVIII\u00a0\u2264\u00a01%) undergoing surgery. All patients had a minimum of 50 exposure days to any FVIII product prior to surgery and no history of inhibitors. A total of 41 procedures (13 orthopaedic, 19 dental and 9 general) were performed in 33 patients aged 4\u201359\u00a0years. Of the 41 procedures, 15 were major surgeries in 13 patients and 26 were minor surgeries in 21 patients. The success rate for haemostatic response was 100% (success was defined as \u2018excellent\u2019 or \u2018good\u2019 haemostatic outcome). Turoctocog alfa consumption on the day of surgery ranged from 27 to 153\u00a0IU\u00a0kg<jats:sup>\u22121<\/jats:sup>. The mean daily dose declined over time, while retaining adequate FVIII coverage as measured by trough levels. Overall, no safety issues were identified. No thrombotic events were observed and none of the patients developed FVIII inhibitors. In conclusion, the present results show that turoctocog alfa was effective in controlling blood loss by obtaining a sufficient haemostatic response in patients with severe haemophilia A undergoing surgery.<\/jats:p>","DOI":"10.1111\/hae.12518","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T09:20:26Z","timestamp":1412241626000},"page":"34-40","source":"Crossref","is-referenced-by-count":46,"title":["Safety and efficacy of turoctocog alfa (NovoEight<sup>\u00ae<\/sup>) during surgery in patients with haemophilia A: results from the multinational guardian<sup>\u2122<\/sup> clinical trials"],"prefix":"10.1111","volume":"21","author":[{"given":"E.","family":"Santagostino","sequence":"first","affiliation":[{"name":"Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ca' Granda Foundation, Maggiore Hospital Policlinico Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Lentz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The University of Iowa Carver College of Medicine Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Misgav","sequence":"additional","affiliation":[{"name":"National Hemophilia Center Chaim Sheba Medical Center affiliated to the Sackler School of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brand","sequence":"additional","affiliation":[{"name":"Division of Hematology University Hospital Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chowdary","sequence":"additional","affiliation":[{"name":"Katharine Dormandy Haemophilia Centre and Thrombosis Unit Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Savic","sequence":"additional","affiliation":[{"name":"Clinic of Hematology Clinical Center of Vojvodina, Faculty of Medicine University of Novi Sad Novi Sad Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kilinc","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology Cukurova University Adana Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Amit","sequence":"additional","affiliation":[{"name":"Israel National Hemophilia Center Tel Hashomer Hospital Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Amendola","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics and Rehabilitation University of Iowa Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. P.","family":"Solimeno","sequence":"additional","affiliation":[{"name":"Haemophilic Arthropathy Treatment Centre \u2018M.G. Gatti Randi\u2019, CTO Hospital Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Saugstrup","sequence":"additional","affiliation":[{"name":"Biostatistics Haemophilia Novo Nordisk A\/S Soeborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Matytsina","sequence":"additional","affiliation":[{"name":"Medical &amp; Science Haemophilia Novo Nordisk A\/S Soeborg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,2]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"60","article-title":"Surgical management of advanced hemophilic arthropathy. An overview of 20\u00a0years' experience","volume":"242","author":"Luck JV","year":"1989","journal-title":"Clin Orthop Relat Res"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2012.01653.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.11.024"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02135.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02333.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12159"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12165"},{"key":"e_1_2_8_9_1","unstructured":"WMA.Declaration of Helsinki \u2010 Ethical Principles for Medical Research Involving Human Subjects.2010."},{"key":"e_1_2_8_10_1","unstructured":"ICH.Tripartite harmonised guideline: Good Clinical Practice: Consolidated Guideline (E6).2010."},{"key":"e_1_2_8_11_1","volume-title":"Guidelines for dental treatment of patients with inherited bleeding disorders","author":"Brewer A","year":"2006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-02-0117"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01978.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02239.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32832c8803"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12518","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.12518","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:24:39Z","timestamp":1695561879000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/hae.12518"],"URL":"https:\/\/doi.org\/10.1111\/hae.12518","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,2]]}}}